
FOCUS 77L is an NGS-based liquid biopsy assay designed for patients with insufficient tissue for molecular testing, when repeat tissue biopsy is not feasible, and/or in cases of disease progression or suspected acquired resistance. By analyzing ctDNA in blood, it enables longitudinal monitoring of the tumor’s molecular profile.
The assay demonstrates high concordance with tissue-based genomic profiling and, in accordance with international guidelines (ASCO and ESMO), enables the sensitive detection of resistance-associated alterations that may emerge during treatment.
Cancer Type: All solid tumors*
* For patients with non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) who have progressive disease and insufficient tissue for molecular analysis, liquid biopsy (cfDNA) is recognized by NCCN Guidelines as a critical diagnostic approach.
Technical Specifications | |
|---|---|
Method: NGS – Hybrid Capture | Coverage: ~10,000x (High Sensitivity) |
Coverage: 77 Genes (Included in NCCN guidelines) ALK, NTRK1, FGFR2, FGFR3, RET, and ROS1 (Fusions); EGFR, ERBB2, and MET (CNVs) genes Genetic Alterations Analyzed: Detects SNV, Indel, Fusion, and CNV variants with a limit of detection (LoD) down to 0.1%. | |
Assay Kit: ROCHE AVENIO ctDNA kit | Sequencing System: İlumina NextSeq 550 DX (CE-IVD approved) |
Bioinformatics System: Avenio | Accreditation: GENQA External Quality Assessment (EQA) & CAP Accreditation |
Other Features: The test features a Positive Predictive Value (PPV) of >99%, significantly minimizing false-positive rates. | |
Sample Requirements: 2 Streck Tubes Turnaround Time (TAT): 10–14 days | |
* Please contact our laboratory for detailed sample submission requirements.
FOCUS 77 Liquid is performed in accordance with the requirements of the EMQN External Quality Assessment (EQA) program.


![]()
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, Şişli / Istanbul
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00
The content provided on this site is intended for informational purposes only and is not a substitute for professional medical advice or diagnosis. Always seek the advice of a qualified healthcare provider for any medical evaluation, diagnosis, or treatment.
All rights reserved © 2026. Explicit Consent Statement | Last Updated: 27.04.2026 14:00 / mowaffak@hotmail.com
I acknowledge that I have read and understood the Privacy Notice provided by Nesiller Genetic Laboratories, acting as the data controller. The Privacy Notice clearly and comprehensively explains the identity of the data controller, the categories of personal data to be processed, the purposes of processing, the recipient groups to whom personal data may be transferred, the methods and legal grounds for data collection, and my rights as a data subject. I have also been informed that more detailed information is available in the Personal Data Retention and Destruction Policy and in the records maintained within the VERBIS system at the address indicated.
In addition to the matters described in the Privacy Notice, I freely give my explicit consent, with full awareness of the meaning, legal consequences, and potential future implications of this declaration, to the processing of my name, surname, email address, telephone number, company name, country, city, and address solely for the purposes of product and service promotions, gifts, discounts, new opportunities and special offers, announcements, advertisements, campaigns, personalized marketing activities, event invitations, and special occasion greetings, and for being contacted by email and SMS in accordance with the Law on the Regulation of Electronic Commerce and its applicable secondary legislation.
I further consent to the sharing of these personal data with companies providing SMS and email delivery services and marketing consultancy services with which Nesiller Genetic Laboratories has contractual relationships, solely for the purposes specified above.